Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen, Ira Mellman · Immunity · 2013
Cited by 6,888 works. doi:10.1016/j.immuni.2013.07.012 Open-access PDF
Authors
References
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- Cancer immunoediting: from immunosurveillance to tumor escape
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- Cancer immunotherapy comes of age
- Tumor Antigens Recognized by T Lymphocytes
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity